Acromegaly results in abnormal bone and tissue growth, causing enlarged feet, hands, facial features and inner organs. Credit: Wysocka Malgorzata / Shutterstock.

Swedish pharmaceutical company Camurus has reported positive results from the Phase III ACROINNOVA 2 study, which assessed the efficacy and safety of octreotide subcutaneous (SC) depot (CAM2029) in patients with acromegaly.

Acromegaly is a slowly progressive disease caused by a tumour of the pituitary gland producing excess growth hormone and stimulating increased insulin growth factor-1 (IGF-1) levels.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

This results in abnormal growth of bone and tissue, causing enlarged hands, feet, facial features and inner organs, as well as symptoms such as fatigue, joint pain, headache, visual field defects, excessive sweating and paresthaesia.

CAM2029 is an investigational, ready-to-use octreotide designed to treat acromegaly in addition to gastroentero-pancreatic neuroendocrine tumours and polycystic liver disease.

The drug is currently being reviewed by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), with the FDA expected to issue a first approval decision by 21 October.

See Also:

The ACROINNOVA 2 trial’s primary focus was on safety over a year of treatment, with the drug demonstrating a favourable profile.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The study involved 135 patients, with 81 new participants and 54 from the previous ACROINNOVA 1 trial.

Its primary endpoint was CAM2029’s safety over 52 weeks, while secondary endpoints included biochemical control rates, symptom scores and patient-reported outcomes.

CAM2029 was found to be well-tolerated in the trial, with no new safety concerns compared to standard-of-care somatostatin receptor ligands.

Adverse events were mostly mild to moderate, with the most common being injection site reactions and gastrointestinal issues.

Camurus CSO president and CEO Fredrik Tiberg said: “Today’s results from ACROINNOVA 2 highlight the long-term safety profile and efficacy of octreotide SC depot in patients with acromegaly, including patients with uncontrolled disease on standard-of-care.

“These data further strengthen the evidence base for CAM2029 octreotide SC depot as a new treatment option for people living with acromegaly, if approved.”